

Attorney Docket No. 5218-39C

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Anagnostou et al.

Application No.: 09/525,808

Filed: March 15, 2000

For: Method of Treating Endothelial Injury

Confirmation No.: 9764

Group Art Unit: 1643

Examiner: Christopher H. Yaen

Date: October 28, 2005

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450



**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(c)**

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

This Information Disclosure is submitted in accordance with 37 C.F.R. § 1.97(b)(4), before the mailing of a first action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

Shawna Cannon Lemon
Registration No. 53,888

Myers Bigel Sibley & Sajovec, P.A.

P. O. Box 37428

Raleigh, North Carolina 27627

Telephone: (919) 854-1400

Facsimile: (919) 854-1401

Customer No. 20792


CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 28, 2005.

Susan E. Freedman

Date of Signature: October 28, 2005

Substitute form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/525,808
		Filing Date	March 15, 2000
		First Named Inventor	Athanasius Anagnostou
		Group Art Unit	1643
		Examiner Name	Christopher H. Yaen
Sheet 1 of 1	Attorney Docket Number	5218-39C	



U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		

OTHER NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	1.	Bokkel et al. Proceedings of the American Society of Clinical Oncology 13: 234 (1994)		
	2.	Carlini et al. "Recombinant Human Erythropoietin (rHuEPO) Increases Endothelin-1 Release by Endothelial Cells" Kidney International 43: 1010-1014		
	3.	Demer Bio/Technology 1994 12:320		
	4.	Freshney Culture of Animal Cells, A Manual of Basic Technique Alan R. Liss, Inc. 1983 NY p. 4		
	5.	Gura Science 1997 278: 1041-1042		
	6.	Hockel et al. "Therapeutic Angiogenesis" Arch Surg 128: 423-429 (1993)		
	7.	M. Cazzola; "Erythropoietin: biology and clinical applications"; Trends in Experimental and Clinical Medicine, 3:344-361 (1993)		
	8.	Miller et al. "Phase I-II Trial of Erythropoietin in the Treatment of Cisplatin-Associated Anemia" J Natl Cancer Inst 84(2): 98-103 (1992)		
	9.	Plantani et al. J Clinical Oncology 1991 pp. 20021-2026		
	10.	Rubins "Response to Treatment with Human Recombinant Erythropoietin" Annals of Internal Medicine 122(9): 676-677 (1995)		
	11.	Sungur "Renal Cell Carcinoma and Erythropoietin" Annals of Internal Medicine 123(9): 732-733 (1995)		
	12.	Wood et al. J Clinical Investigation 1995 95: 1650-1659		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.